An investigational oral GLP-1 receptor agonist helped adults with overweight or obesity lose up to 11.3% more body weight than placebo over 36 weeks, according to a phase 2b study published July 1 in Nature Medicine.
Here are four things to know from the study:
- The randomized, double-blind, placebo-controlled ACCESS trial enrolled 230 adults across 38 U.S. sites. Placebo-adjusted weight loss reached 8.2%, 9.8% and 11.3% in the 45 milligram, 90 milligram and 120 milligram dose groups, respectively.
- Researchers observed no apparent weight-loss plateau, with investigators reporting that participants continued losing weight through the end of the 36-week double-blind study. An interim analysis of the ongoing open-label extension also showed continued weight loss beyond the initial treatment period.
- Most participants achieved clinically meaningful weight loss. Among those receiving the 120-milligram dose, 86% lost at least 5% of their body weight, 70% lost at least 10% and 38% lost at least 15%.
- Gastrointestinal side effects were the most common adverse events. Treatment-related discontinuations across the active treatment groups totaled 10.4%, and investigators reported no cases of drug-induced liver injury.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
